Yury Verlinsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yury Verlinsky has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anver Kuliev
Reproductive Genetics Institute, Chicago, IL, USA
9 shared publications Oleg Verlinsky
Reproductive Genetics Institute, Chicago, IL, USA
5 shared publicationsSvetlana Rechitsky
5 shared publicationsC Strom
Reproductive Genetics Institute, Chicago, IL, USA
3 shared publicationsChristina Masciangelo
3 shared publicationsO Verlinsky
Reproductive Genetics Institute, Chicago, IL, USA
3 shared publications
Latest Publications
- 31 December 2007
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 14, 102-103
Ethics of preimplantation genetic diagnosis
- 31 December 2007
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 14, 102-103
Ethics of preimplantation genetic diagnosis
- 1 June 2006
- Published by Elsevier in Fertility and Sterility
- Vol. 85 (6) , 1826-1829
Multiple micromanipulations for preimplantation genetic diagnosis do not affect embryo development to the blastocyst stage
- 1 June 2006
- Published by Elsevier in Fertility and Sterility
- Vol. 85 (6) , 1826-1829
Multiple micromanipulations for preimplantation genetic diagnosis do not affect embryo development to the blastocyst stage
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 10, 24-26
Designing babies: what the future holds
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 10, 24-26
Designing babies: what the future holds
- Open Access
- 1 September 2004
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 10 (5) , 401-407
Meiotic and mitotic nondisjunction: lessons from preimplantation genetic diagnosis
Direct testing of the outcome of the first and second meiotic divisions has become possible with the introduction of preimplantation genetic diagnosis (PGD) for aneuploidies. Testing of oocytes by fluorescent in situ hybridization (FISH) analysis of the first and second polar bodies showed that more than half of oocytes from the IVF patients aged 35 years and older had chromosomal abnormalities, which originated from errors in meiosis I or meiosis II, or both: 41.9% of oocytes were aneuploid after meiosis I and 37.3% aneuploid after meiosis II, with 29.1% of these oocytes having both meiosis I and meiosis II errors. As a result, one third of oocytes detected as normal after meiosis I contained the meiosis II errors, and two thirds of those with meiosis II errors were already abnormal following meiosis I. Although the rates of chromosomal abnormalities deriving from meiosis I and II were comparable, meiosis I errors predominantly resulted in extra chromosome (chromatid) material in oocytes, in contrast to a random distribution of extra and missing chromatids after meiosis II. The majority of meiosis I abnormalities were represented by chromatid errors, which seem to be the major source of chromosomal abnormalities in the resulting embryos. Approximately one third of aneuploid oocytes deriving from sequential errors in the first and second meiotic divisions resulted in a balanced karyotype, representing a possible phenomenon of “aneuploidy rescue” during the second meiotic division. However, the majority of the embryos resulting from such oocytes appeared to be abnormal for the same or different chromosome(s), or were mosaic, suggesting a possible predisposition of the resulting embryos to further mitotic errors. Although the origin of a high frequency of mosaicism at the cleavage stage is not sufficiently understood, the mosaic embryos may originate from the chromosomally abnormal oocytes, as a result of a “trisomy rescue” mechanism during the first mitotic divisions, which renders polar body FISH analysis to have important clinical value for reliable pre-selection of aneuploidy-free embryos for transfer.
- 1 September 2004
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 10 (5) , 401-407
Open AccessMeiotic and mitotic nondisjunction: lessons from preimplantation genetic diagnosis
Direct testing of the outcome of the first and second meiotic divisions has become possible with the introduction of preimplantation genetic diagnosis (PGD) for aneuploidies. Testing of oocytes by fluorescent in situ hybridization (FISH) analysis of the first and second polar bodies showed that more than half of oocytes from the IVF patients aged 35 years and older had chromosomal abnormalities, which originated from errors in meiosis I or meiosis II, or both: 41.9% of oocytes were aneuploid after meiosis I and 37.3% aneuploid after meiosis II, with 29.1% of these oocytes having both meiosis I and meiosis II errors. As a result, one third of oocytes detected as normal after meiosis I contained the meiosis II errors, and two thirds of those with meiosis II errors were already abnormal following meiosis I. Although the rates of chromosomal abnormalities deriving from meiosis I and II were comparable, meiosis I errors predominantly resulted in extra chromosome (chromatid) material in oocytes, in contrast to a random distribution of extra and missing chromatids after meiosis II. The majority of meiosis I abnormalities were represented by chromatid errors, which seem to be the major source of chromosomal abnormalities in the resulting embryos. Approximately one third of aneuploid oocytes deriving from sequential errors in the first and second meiotic divisions resulted in a balanced karyotype, representing a possible phenomenon of “aneuploidy rescue” during the second meiotic division. However, the majority of the embryos resulting from such oocytes appeared to be abnormal for the same or different chromosome(s), or were mosaic, suggesting a possible predisposition of the resulting embryos to further mitotic errors. Although the origin of a high frequency of mosaicism at the cleavage stage is not sufficiently understood, the mosaic embryos may originate from the chromosomally abnormal oocytes, as a result of a “trisomy rescue” mechanism during the first mitotic divisions, which renders polar body FISH analysis to have important clinical value for reliable pre-selection of aneuploidy-free embryos for transfer.
- 1 January 2004
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 9 (6) , 623-629
Morula-derived human embryonic stem cells
- 1 January 2004
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 9 (6) , 623-629
Morula-derived human embryonic stem cells
- 1 October 2003
- Published by Elsevier in Fertility and Sterility
- Vol. 80 (4) , 869-870
Preimplantation diagnosis for aneuploidies using fluorescence in situ hybridization or comparative genomic hybridization
- 1 October 2003
- Published by Elsevier in Fertility and Sterility
- Vol. 80 (4) , 869-870
Preimplantation diagnosis for aneuploidies using fluorescence in situ hybridization or comparative genomic hybridization
- 27 February 2002
- Published by American Medical Association (AMA) in JAMA
- Vol. 287 (8) , 1018-1021
Preimplantation Diagnosis for Early-Onset Alzheimer Disease Caused by V717L Mutation
Research from JAMA — Preimplantation Diagnosis for Early-Onset Alzheimer Disease Caused by V717L Mutation — ContextIndications for preimplantation genetic diagnosis (PGD) have recently been expanded to include disorders with genetic predisposition to allow only embryos free of predisposing genes to be preselected for transfer back to patients, with no potential for pregnancy termination.ObjectiveTo perform PGD for early-onset Alzheimer disease (AD), determined by nearly completely penetrant autosomal dominant mutation in the amyloid precursor protein (APP) gene.DesignAnalysis undertaken in 1999-2000 of DNA for the V717L mutation (valine to leucine substitution at codon 717) in the APP gene in the first and second polar bodies, obtained by sequential sampling of oocytes following in vitro fertilization, to preselect and transfer back to the patient only the embryos that resulted from mutation-free oocytes.SettingAn in vitro fertilization center in Chicago, Ill.PatientsA 30-year-old AD-asymptomatic woman with a V717L mutation that was identified by predictive testing of a family with a history of early-onset AD.Main Outcome MeasuresResults of mutation analysis; pregnancy outcome.ResultsFour of 15 embryos tested for maternal mutation in 2 PGD cycles, originating from V717L mutation–free oocytes, were preselected for embryo transfer, yielding a clinical pregnancy and birth of a healthy child free of predisposing gene mutation according to chorionic villus sampling and testing of the neonate's blood.ConclusionThis is the first known PGD procedure for inherited early-onset AD resulting in a clinical pregnancy and birth of a child free of inherited predisposition to early-onset AD.
- 27 February 2002
- Published by American Medical Association (AMA) in JAMA
- Vol. 287 (8) , 1018-1021
Preimplantation Diagnosis for Early-Onset Alzheimer Disease Caused by V717L Mutation
Research from JAMA — Preimplantation Diagnosis for Early-Onset Alzheimer Disease Caused by V717L Mutation — ContextIndications for preimplantation genetic diagnosis (PGD) have recently been expanded to include disorders with genetic predisposition to allow only embryos free of predisposing genes to be preselected for transfer back to patients, with no potential for pregnancy termination.ObjectiveTo perform PGD for early-onset Alzheimer disease (AD), determined by nearly completely penetrant autosomal dominant mutation in the amyloid precursor protein (APP) gene.DesignAnalysis undertaken in 1999-2000 of DNA for the V717L mutation (valine to leucine substitution at codon 717) in the APP gene in the first and second polar bodies, obtained by sequential sampling of oocytes following in vitro fertilization, to preselect and transfer back to the patient only the embryos that resulted from mutation-free oocytes.SettingAn in vitro fertilization center in Chicago, Ill.PatientsA 30-year-old AD-asymptomatic woman with a V717L mutation that was identified by predictive testing of a family with a history of early-onset AD.Main Outcome MeasuresResults of mutation analysis; pregnancy outcome.ResultsFour of 15 embryos tested for maternal mutation in 2 PGD cycles, originating from V717L mutation–free oocytes, were preselected for embryo transfer, yielding a clinical pregnancy and birth of a healthy child free of predisposing gene mutation according to chorionic villus sampling and testing of the neonate's blood.ConclusionThis is the first known PGD procedure for inherited early-onset AD resulting in a clinical pregnancy and birth of a child free of inherited predisposition to early-onset AD.
- 1 January 2002
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 5 (2) , 148-155
Preimplantation genetic diagnosis for cancer predisposition
- 1 January 2002
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 5 (2) , 148-155
Preimplantation genetic diagnosis for cancer predisposition
- 1 January 2002
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 4 (1) , 38-42
Polar body-based preimplantation diagnosis for X-linked disorders
- 1 January 2002
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 4 (1) , 38-42
Polar body-based preimplantation diagnosis for X-linked disorders
- 1 January 2002
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 4 (3) , 218-222
Preimplantation diagnosis for neurofibromatosis
- 1 January 2002
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 4 (3) , 218-222
Preimplantation diagnosis for neurofibromatosis